Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/19379
DOI URL: http://dx.doi.org/10.21474/IJAR01/19379

RESEARCH ARTICLE

WHAT IS THE ROLE OF IMMUNOTHERAPY IN NEUROBLASTOMA?

Rishita Bhattacharjee

Manuscript Info

Manuscript History
Received: 25 June 2024
Final Accepted: 27 July 2024
Published: August 2024

Abstract

This research paper delves into the role of immunotherapy in treating neuroblastoma, a pediatric cancer characterized by its origin in neural crest cells and its highly variable clinical presentation. Neuroblastoma exhibits a broad spectrum of behaviors, from spontaneous regression to aggressive metastasis, posing unique challenges to conventional treatment strategies such as chemotherapy and surgical intervention. Immunotherapy emerges as a critical advancement, utilizing the body's immune system to target and eradicate cancer cells through mechanisms that engage both innate and adaptive immune responses. The paper focuses on several immunotherapeutic strategies, particularly the application of monoclonal antibodies like dinutuximab, which targets the GD2 antigen—a molecule extensively expressed on neuroblastoma cells. This approach capitalizes on the body's natural immune functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), to destroy cancer cells. Furthermore, the exploration of immune checkpoint inhibitors that help restore immune system activity suppressed by cancer cells, and adoptive cell therapies, where T cells are engineered to fight cancer directly, illustrates the dynamic interaction between neuroblastoma and the immune system. Additionally, the paper outlines the scientific challenges in integrating immunotherapy with existing treatments, emphasizing the necessity for precise biomarkers that enhance the predictability of treatment responses and allow for the customization of therapeutic approaches to individual patient needs. The potential side effects and the variable efficacy observed among patients highlights the complexity of tailoring immunotherapy in pediatric oncology. This review aims to provide a foundational understanding of how immunotherapy could revolutionize neuroblastoma treatment, improving outcomes for patients through a deeper scientific understanding and targeted approach.

Introduction:-

Immunotherapy represents a promising frontier in the treatment of neuroblastoma, a complex childhood cancer arising from neural crest cells involved in the sympathetic nervous system. Despite advances in conventional treatments like chemotherapy and surgery, neuroblastoma often presents unique challenges due to its variable behavior, ranging from spontaneous regression to aggressive metastatic disease. Immunotherapy, by leveraging the

Corresponding Author:- Rishita Bhattacharjee

body's own immune system to recognize and eliminate cancer cells, offers a potentially transformative approach to these challenges. This treatment modality has gained significant traction, spurred by promising outcomes and the advent of novel therapeutic agents that target specific aspects of the immune response to cancer.

The application of immunotherapy in neuroblastoma primarily revolves around enhancing the efficacy and specificity of immune responses against tumor cells. Key strategies include monoclonal antibodies that target tumor-specific antigens. Other strategies involve immune checkpoint inhibitors that help overcome cancer-induced immune suppression, and adoptive cell therapies that involve the transfer of ex vivo activated immune cells capable of targeting cancer cells. Among these, monoclonal antibodies like dinutuximab, which targets the GD2 antigen highly expressed on neuroblastoma cells, have shown considerable success, improving survival rates in high-risk cases when used in combination with other therapies.

However, the integration of immunotherapy into existing neuroblastoma treatment protocols requires careful consideration of its indications, efficacy, and potential side effects. The variability in patient responses highlights the need for precise biomarkers to predict treatment outcomes and tailor therapies to individual patients. This paper aims to explore the role of immunotherapy in neuroblastoma, evaluating its effectiveness, challenges, and future directions. Through a comprehensive review of current research and clinical trials, this discussion will contribute to a deeper understanding of how immunotherapy can be optimized to improve therapeutic outcomes in neuroblastoma patients.

Introduction to Neuroblastoma

Neuroblastoma predominantly affects children under the age of five, with key genetic mutations such as MYCN oncogene amplification and alterations in tumor suppressor genes like TP53 and ALK. Approximately 1-2% of cases show a hereditary tendency, involving genes such as PHOX2B. Tumor formation occurs when immature nerve cells fail to mature, leading to undifferentiated cell growth in the sympathetic nervous system. Neuroblastoma is known for its early metastasis to organs like bones, liver, and skin. Clinical symptoms vary widely, including abdominal distension, weight loss, fatigue, and bone pain. Staging, following the International Neuroblastoma Staging System (INSS), ranges from localized tumors (Stage 1) to widespread metastasis (Stage 4). Diagnosis involves imaging studies (ultrasound, CT, MRI, MIBG scans) and crucial biopsy and molecular testing, particularly MYCN amplification analysis. Treatment modalities include surgical resection, chemotherapy (cisplatin, etoposide), radiation therapy, and promising immunotherapeutic agents like anti-GD2 antibodies such as dinutuximab. Dinutuximab is a monoclonal antibody that targets GD2, a molecule highly expressed in neuroblastoma cells, eliciting immune responses that lead to cancer cell destruction. Used in combination with other therapies, it has demonstrated efficacy in improving outcomes for high-risk neuroblastoma patients by enhancing event-free and overall survival rates. Ongoing research aims to optimize treatment protocols and identify predictive biomarkers to further enhance the effectiveness of dinutuximab-based immunotherapy in pediatric oncology. Neuroblastoma stands as one of the most enigmatic and complex pediatric cancers, characterized by its heterogeneity in clinical presentation, diverse biological features, and varied outcomes. Neuroblastoma constitutes a significant portion of pediatric malignancies, accounting for approximately 6-10% of all childhood cancers. It predominantly affects infants and young children, with nearly half of the cases diagnosed before the age of two, and the median age at diagnosis lies around 17 months. Despite its rarity in adults, its incidence displays slight variations across different demographic regions, with higher rates observed in Caucasians compared to other ethnic groups. Furthermore, there seems to be a male predominance in neuroblastoma cases. At its core, neuroblastoma arises from irregular development and differentiation of neural crest cells, leading to the formation of tumors in sympathetic nervous system tissues, most commonly in the adrenal medulla or along the sympathetic chain. Molecular studies have shed light on the intricate genetic landscape underlying neuroblastoma, revealing a myriad of genetic alterations that contribute to its pathogenesis. Amplification of the MYCN oncogene represents a hallmark genetic aberration in aggressive forms of neuroblastoma, while mutations in genes such as ALK, PHOX2B, and ATRX have been implicated in disease progression and prognosis. Moreover, the tumor microenvironment plays a crucial role in neuroblastoma biology, with interactions between cancer cells, stromal cells, and immune cells influencing tumor growth, invasion, and response to therapy. Neuroblastomas exhibit remarkable structural diversity, ranging from well-differentiated ganglioneuromas to undifferentiated and highly malignant neuroblastic tumors. The International Neuroblastoma Pathology Classification (INPC) categorizes neuroblastoma into different histologic subtypes based on cellular features, degree of differentiation, and presence of stromal elements. Furthermore, immunohistochemical and molecular analyses aid in refining diagnosis and risk stratification, enabling clinicians to tailor treatment strategies based on the tumor's biological characteristics.

Current Treatments for Neuroblastoma

Surgical resection is often the initial step in managing neuroblastoma, particularly for localized tumors. Complete resection can lead to favorable outcomes, especially in low-risk disease. However, surgery may not be feasible in cases of extensive metastatic spread or involvement of critical structures. Additionally, residual disease post-surgery can necessitate further adjuvant therapies. Chemotherapy plays a central role in neuroblastoma treatment, either as induction therapy to shrink tumors prior to surgery or as part of multimodal therapy to eradicate residual disease. Regimens typically include drugs such as cisplatin, doxorubicin, vincristine, and etoposide. While chemotherapy has improved survival rates, it is associated with significant toxicity, including myelosuppression, neurotoxicity, and long-term sequelae such as secondary malignancies. Radiation therapy is used to target residual or metastatic disease following surgery and chemotherapy, particularly in high-risk cases. It can provide local control and palliation but carries the risk of long-term side effects. These include growth impairment, neurocognitive deficits, and secondary malignancies, which are particularly concerning in the pediatric population. Immunotherapy, particularly with monoclonal antibodies targeting disialoganglioside GD2 (e.g., dinutuximab) which is a glycolipid antigen abundantly expressed on neuroblastoma cells, serving as a promising therapeutic target for cancer treatment. Its selective presence on tumor cells makes it an attractive focus for immunotherapy, particularly in combination with other therapies.[2] Despite challenges such as side effects and variable patient response, ongoing research aims to optimize GD2-targeted immunotherapy for improved efficacy and safety in pediatric oncology, emerging as a promising approach for neuroblastoma. These antibodies facilitate antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity against neuroblastoma cells. However, not all patients respond to immunotherapy, and it can be associated with infusion reactions and neuropathic pain. Differentiation therapy such as retinoic acid, a differentiating agent, is used in the treatment of high-risk neuroblastoma, particularly in maintenance therapy following induction chemotherapy and surgery. It promotes maturation of neuroblastoma cells into benign ganglioneuroma-like cells, reducing tumor aggressiveness. Benign ganglioneuroma cells are composed of mature ganglion cells, Schwann cells, and fibrous tissue. Their presence within tumors indicates a potentially less aggressive nature and may influence treatment decisions and prognosis. Understanding these cells' characteristics and diagnostic significance is essential for accurate tumor classification and guiding appropriate management strategies in neuroblastoma and related neuroblastic tumors. Nevertheless, resistance to retinoic acid therapy can develop, limiting its efficacy. Targeted therapy such as molecular profiling has identified several genetic aberrations in neuroblastoma, including amplification of the MYCN oncogene and mutations in ALK and PHOX2B. Targeted therapies aimed at these molecular targets, such as ALK inhibitors (e.g., crizotinib), hold promise for improving outcomes in select patient subsets. However, resistance to targeted agents can develop, necessitating ongoing research into combination therapies and novel targets. Despite significant advances in neuroblastoma treatment, several limitations persist. These include treatment-related toxicities, development of therapy resistance, disease relapse, and challenges in stratifying patients based on risk factors. Future directions in neuroblastoma research include refining risk stratification, exploring new therapeutic targets, and optimizing treatment combinations to improve outcomes while minimizing long-term sequelae. By addressing these challenges, we can hope to continue improving survival rates and quality of life for children with neuroblastoma.

Basics of Immunotherapy

The innate immune system's critical role as the body's initial defense against pathogens. This includes an overview of its various components, such as physical barriers like the skin and mucous membranes, as well as cellular defenders like macrophages, neutrophils, and natural killer cells. Additionally, the recognition mechanisms mediated by pattern recognition receptors (PRRs), which detect conserved molecular patterns shared by different pathogens, are termed Pathogen-Associated Molecular Patterns (PAMPs). The innate immune system lays the foundational groundwork by rapidly identifying and responding to threats, setting the stage for a more tailored and prolonged adaptive response. However, the primary focus in the realm of immunotherapy is on harnessing and enhancing the adaptive immune system, due to its ability to target specific antigens with high precision. Transitioning to adaptive immunity, which highlights its specificity and targeted response to pathogens. This section covers the functions of B and T cells, including antigen presentation, antibody production, and cellular immunity mechanisms. Furthermore, the significance of immunological memory, wherein memory B and T cells persist post-infection, facilitating rapid and heightened responses upon re-exposure to pathogens, a principle exploited in vaccination strategies. The regulation of immune responses, underscoring the importance of self-tolerance mechanisms and the regulatory role of T cells in maintaining immune homeostasis and preventing autoimmune reactions. Subsequently, immunopathology, focusing on hypersensitivity reactions and immunodeficiency disorders, alongside the role of cytokines in mediating immune responses, both pro-inflammatory and anti-inflammatory. Lastly, the burgeoning field of immunotherapy, spotlighting strategies such as cancer immunotherapy and treatments for autoimmune

diseases. This includes insights into checkpoint inhibitors, adoptive T cell transfer, and immunomodulatory drugs, showcasing their potential to enhance the immune system's ability to combat diseases. The immune system is equipped with a sophisticated network of cells and molecules tasked with distinguishing self from nonself-entities, including pathogens and aberrant cells such as cancer cells. Central to immunotherapy is the concept of immune recognition, where immune cells, particularly T cells, recognize specific antigens presented on the surface of cancer cells. This recognition triggers a cascade of immune responses aimed at eliminating the identified threat.One of the main approaches in immunotherapy involves checkpoint inhibition, which aims to unleash the immune system's full potential by overcoming inhibitory signals that dampen immune responses. Checkpoint molecules, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), act as brakes on T cell activity to prevent excessive immune activation. Inhibiting these checkpoints with monoclonal antibodies (e.g., pembrolizumab, ipilimumab) restores T cell function, allowing for enhanced tumor recognition and elimination. Chimeric antigen receptor (CAR) T cell therapy represents a groundbreaking form of immunotherapy that involves genetically modifying patients' T cells to express synthetic receptors targeting tumor-specific antigens. These engineered CAR-T cells are reinfused into the patient, where they seek out and destroy cancer cells bearing the targeted antigen. CAR-T cell therapy has shown remarkable efficacy in hematologic malignancies, leading to durable remissions in patients with refractory or relapsed disease. Monoclonal antibodies (mAbs) are engineered antibodies designed to bind to specific antigens expressed on cancer cells, thereby facilitating immune-mediated destruction. These antibodies can exert their effects through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and blockade of signaling pathways essential for tumor survival and proliferation. Examples of mAb therapies include rituximab for B cell lymphomas and trastuzumab for HER2-positive breast cancer. Cytokines play a crucial role in modulating immune responses by orchestrating communication between immune cells. Cytokine-based immunotherapy involves the administration of recombinant cytokines, such as interleukin-2 (IL-2) and interferons, to augment antitumor immune responses. IL-2, in particular, has been used to stimulate the proliferation and activation of T cells and natural killer (NK) cells, leading to durable responses in select patients with metastatic melanoma and renal cell carcinoma. Therapeutic cancer vaccines aim to stimulate the immune system to recognize and mount an immune response against tumor-specific antigens. These vaccines can consist of whole tumor cells, tumor antigens, or dendritic cells loaded with tumor antigens. By priming the immune system to recognize and target cancer cells, therapeutic vaccines hold promise as a personalized approach to cancer treatment, particularly in preventing disease recurrence.

Immunotherapy Agents & Targets

Conventional treatment modalities like surgery, chemotherapy, and radiation therapy, while effective to some extent, often exhibit limitations in efficacy and are accompanied by debilitating side effects. Consequently, there is a pressing need to explore alternative therapeutic strategies, such as immunotherapy, which harnesses the body's immune system to target and eradicate cancer cells. Cancer is characterized by uncontrolled cellular proliferation, evasion of immune surveillance, and the ability to metastasize to distant sites. Tumor cells employ a myriad of mechanisms to evade immune detection and destruction. One such mechanism involves the downregulation of major histocompatibility complex (MHC) molecules, which present antigens to T cells and regulate immune responses. Divided into MHC class I and II, they bind peptides derived from intracellular or extracellular sources, respectively, for recognition by CD8+ or CD4+ T cells. MHC polymorphism, stemming from highly variable genes, influences immune responsiveness and histocompatibility in organ transplantation, crucial for minimizing graft rejection impairing the presentation of tumor antigens to cytotoxic T cells. The regulation of MHC molecules is crucial in neuroblastoma immunotherapy because these molecules help the immune system recognize and attack cancer cells. Neuroblastoma often presents a challenge as these cells typically have low MHC expression, allowing them to evade immune detection. This evasion necessitates the use of additional therapeutic strategies alongside immunotherapy, such as increasing MHC expression, adopting cell transfer techniques, and combining treatments to enhance the immune response and improve overall treatment effectiveness. Additionally, tumor cells upregulate immune checkpoint proteins, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which inhibit T-cell activation and proliferation. Furthermore, the secretion of immunosuppressive cytokines like transforming growth factor-beta (TGF-β) which is a multifunctional cytokine comprising three isoforms that regulate diverse physiological processes. Its signaling pathways, including canonical Smad and non-canonical pathways, mediate cell growth, differentiation, immune regulation, and tissue remodeling. TGF-β plays a dual role in cancer, acting as a tumor suppressor in normal cells but promoting tumor progression in cancerous contexts, creating an immunosuppressive microenvironment conducive to tumor growth and progression. Immunotherapy agents exert their effects through diverse mechanisms, targeting specific vulnerabilities within the tumor microenvironment. Checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, disrupt inhibitory

signals, thereby unleashing T-cell-mediated antitumor responses. By blocking the interaction between checkpoint proteins and their ligands, these agents restore T-cell function and enhance tumor cell recognition and elimination. Notably, checkpoint inhibitors have demonstrated remarkable efficacy across various malignancies, leading to durable responses in a subset of patients. Adoptive cell therapies, including chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte (TIL) therapy, involve the ex vivo modification and reinfusion of patient-derived immune cells to specifically target tumor-associated antigens. Through genetic engineering techniques, T cells are engineered to express CARs, enabling them to recognize and eliminate cancer cells expressing the corresponding antigen. Similarly, TIL therapy involves the isolation and expansion of tumor-specific T cells from the patient's own tumor tissue, followed by reinfusion to mount a targeted immune response against the tumor. Furthermore, cytokine-based therapies, such as interleukin-2 (IL-2) and interferon-alpha (IFN-α), exert pleiotropic effects on the immune system, enhancing the proliferation, activation, and cytotoxicity of effector cells. While these therapies have demonstrated clinical efficacy, they are often associated with significant toxicity profiles, necessitating careful patient selection and management. By targeting specific vulnerabilities within the tumor microenvironment, immunotherapy agents disrupt immunosuppressive mechanisms and unleash potent antitumor immune responses. The pressing need for immunotherapy emerges directly from the limitations of conventional cancer treatments such as surgery, chemotherapy, and radiation therapy. While potentially effective, they often fail to completely eradicate cancer due to its complex immune evasive tactics. Immunotherapy's relevance to the main theme is highlighted by its innovative approach in re-engaging the immune system to specifically and efficiently target cancer cells, thereby overcoming the mechanisms tumors use to evade immune surveillance. This shift towards using the body's own immune mechanisms to fight cancer aligns with a broader therapeutic goal: to achieve higher efficacy with fewer side effects compared to traditional treatments. By directly linking tumor biology, immune evasion, and therapeutic intervention, immunotherapy presents a strategic pivot in cancer treatment. Overall, aiming to transform patient outcomes by harnessing the precision and adaptability of the immune system.

Immunotherapy in Neuroblastoma

Monoclonal antibodies (mAbs) have transformed the perspective of cancer therapy by offering a highly targeted approach to combat malignancies, including neuroblastoma, a challenging pediatric cancer. Bite (Bi-specific T-cell engager) monoclonal antibodies are engineered molecules designed to bridge T cells to cancer cells. They comprise two different antigen-binding sites: one targeting a T-cell-specific antigen (usually CD3) and the other targeting a tumor-associated antigen present on neuroblastoma cells. This configuration activates T cells and directs their cytotoxic activity towards the cancer cells, leading to tumor cell lysis. Dinutuximab, a monoclonal antibody targeting GD2, a disialoganglioside prevalent on neuroblastoma cells, has shown significant efficacy in improving survival rates in high-risk neuroblastoma patients when combined with GM-CSF, IL-2, and isotretinoin. This therapy exemplifies the successful application of monoclonal antibodies in neuroblastoma, marking a paradigm shift in treatment strategies. The binding of BiTE antibodies to CD3 on T cells and GD2 on neuroblastoma cells triggers a series of immunological responses. This culminates in the activation and proliferation of T cells, their migration to the tumor site, and the targeted destruction of tumor cells. This approach harnesses the body's immune system to fight cancer, reducing reliance on conventional chemotherapy and its associated toxicities. These antibodies are engineered to target specific antigens present on the surface of cancer cells, with GD2 being a prime example in the context of neuroblastoma. This surface molecule, while minimally expressed in normal tissues, is abundantly present on neuroblastoma cells, making it an ideal target for therapy. The binding of mAbs to the GD2 antigen triggers a cascade of immune responses, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) which effectively leads to cancer cell destruction. Moreover, these antibodies have the potential to block critical signaling pathways essential for tumor growth and survival, adding another layer to their antitumor activity. Dinutuximab (Unituxin™) stands out as a pioneering example of GD2-directed monoclonal antibody therapy. Approved by the FDA for use in children with high-risk neuroblastoma, Dinutuximab has significantly improved survival rates when used in conjunction with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin. This combination therapy exemplifies how mAbs can be integrated into broader treatment regimens to enhance patient outcomes, demonstrating the profound impact of targeted immune system engagement in combating cancer. Expanding beyond monoclonal antibodies, the realm of drug-conjugated antibodies introduces a potent dual-threat against cancer cells. Drug-conjugated antibodies (DCAs) are a form of targeted therapy that combines the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapy drugs. These conjugates specifically target and bind to antigens on cancer cells, delivering a highly potent cytotoxic agent directly to the tumor, thereby minimizing systemic exposure and reducing side effects. Lorvotuzumabmertansine is an example of a DCA targeting CD56, which is overexpressed in neuroblastoma cells. It has been evaluated in clinical trials for its potential to deliver cytotoxic agents directly to tumor cells, demonstrating

a novel approach to targeting neuroblastoma. The selective targeting of neuroblastoma cells by DCAs allows for the direct delivery of cytotoxic agents to the tumor, sparing normal cells and reducing systemic toxicity. This specificity enhances the therapeutic index of potent chemotherapy drugs, potentially leading to improved outcomes in neuroblastoma patients. These innovative constructs link the specificity of mAbs with powerful cytotoxic drugs, allowing for the direct delivery of lethal payloads to tumor cells. The mechanism involves the antibody binding to a specific tumor antigen, followed by internalization of the conjugate and subsequent release of the cytotoxic agent within the cancer cell, leading to targeted cell death. While this approach is still under exploration for neuroblastoma, its potential is underscored by successes in other cancers, such as Brentuximab vedotin (Adcetris®) for lymphoma, which targets the CD30 molecule on lymphoma cells to deliver a chemotherapeutic agent. The exploration of similar drug-conjugated antibodies targeting GD2 in neuroblastoma promises to open new frontiers in the targeted therapy of this malignancy. Cellular therapies, including CAR-T (Chimeric Antigen Receptor T-cells) and SynNotch T cells, represent a revolutionary approach to cancer treatment. CAR-T therapy involves genetically engineering a patient's T cells to express a chimeric antigen receptor that specifically recognizes a tumor antigen. SynNotch technology enables the engineering of T cells with synthetic Notch receptors that can be programmed to induce specific cellular responses upon recognizing a tumor antigen. Although still in the early stages of research for neuroblastoma, CAR-T cell therapy targeting GD2 has shown promising results in preclinical models, indicating a potential for translating this success into clinical applications. SynNotch T cells represent an even more novel approach, with the potential to provide highly customizable and controllable therapy options for neuroblastoma in the future. The direct targeting and activation of T cells against neuroblastoma cells lead to enhanced tumor cell destruction and the potential for long-term immunological memory against the tumor, offering a promising avenue for durable responses and possibly even cures in some cases. In the innovative field of cellular therapies, CAR T cell therapy and SynNotch T cells represent groundbreaking advancements. CAR T cell therapy involves reprogramming the patient's T cells to express chimeric antigen receptors that specifically recognize and attack tumor cells expressing the target antigen, such as GD2 in neuroblastoma. This personalized approach has shown promising results, with several clinical trials reporting remissions in neuroblastoma patients. The ability of these engineered T cells to directly kill cancer cells offers a powerful new tool in the fight against neuroblastoma. SynNotch T cells, an advanced iteration of cellular therapy, are engineered to require a secondary signal for activation, allowing for more precise targeting and minimizing off-target effects. While still in the early stages of clinical development, SynNotch T cells hold immense promise for enhancing the specificity and safety of cellular immunotherapies, potentially revolutionizing the treatment of neuroblastoma and other cancers. CAR T-cell therapy modifies T cells to express Chimeric Antigen Receptors (CARs) that directly recognize and kill cancer cells by binding to specific antigens on their surface, which can sometimes lead to off-target effects and severe immune reactions. SynNotch technology, on the other hand, uses a gated activation system where T cells are engineered with synthetic Notch (synNotch) receptors that must first recognize a specific tumor antigen to unlock and express a CAR, allowing for a more controlled and localized immune response. This method of conditional CAR expression via synNotch signaling enhances safety by reducing unintended immune activation against non-tumor cells, potentially preventing complications like cytokine release syndrome (CRS) by targeting therapy only to the cancerous environment. Checkpoint inhibitors target immune checkpoints like PD-1 and CTLA-4, proteins that act as brakes on the immune system, preventing overly aggressive responses that could damage healthy tissues. Tumors exploit these checkpoints to avoid immune detection. Inhibiting these checkpoints can unleash the immune system to attack cancer cells. For example in the clinical setting Nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor) are checkpoint inhibitors that have shown efficacy in various cancers. Their potential in neuroblastoma is being explored, with the hypothesis that releasing the immune system's brakes could lead to effective tumor eradication. The blockade of PD-1 and CTLA-4 checkpoints revitalizes the patient's immune response against cancer, enhancing T-cell activation, proliferation, and tumor infiltration. This reactivated immune system can recognize and destroy neuroblastoma cells more effectively. Checkpoint inhibitors, targeting PD-1 and CTLA-4 pathways, have heralded a new era in cancer immunotherapy by reactivating T cells to recognize and eliminate cancer cells. These therapies work by blocking the mechanisms cancer cells use to evade immune detection, effectively lifting the veil of immune tolerance that allows tumors to flourish. Although checkpoint inhibitors have dramatically changed the treatment landscape for adult malignancies, their application in pediatric cancers like neuroblastoma is still being investigated. Early clinical trials are exploring their efficacy in neuroblastoma, both as standalone treatments and in combination with other therapies, highlighting their potential to significantly enhance immune responses against this pediatric cancer. Vaccine-based strategies in neuroblastoma seek to mobilize the immune system against the cancer by introducing tumor antigens in a manner that stimulates a targeted immune response. Cancer vaccines aim to prime the immune system against tumor antigens, enhancing its ability to recognize and destroy cancer cells. Peptide vaccines introduce specific tumor antigens to the immune system, while dendritic cell (DC) vaccines involve culturing a patient's dendritic cells with

tumor antigens before reintroducing them to the patient, thereby educating the immune system to target the cancer. Peptide vaccines targeting specific neuroblastoma antigens are under investigation, with some showing promise in early clinical trials. DC vaccines, engineered to present neuroblastoma antigens, are also being explored, with potential for personalized immunotherapy approaches. Vaccination against tumor antigens leads to the activation and expansion of antigen-specific T cells, which can then seek out and destroy neuroblastoma cells across the body. This strategy aims to not only treat existing disease but also prevent recurrence, offering a proactive approach to long-term cancer management. Peptide vaccines and dendritic cell vaccines are at the forefront of this research, aiming to prime the immune system to recognize and attack neuroblastoma cells. Dendritic cell vaccines, in particular, involve exposing patient-derived dendritic cells to neuroblastoma antigens, then reintroducing them to the patient to activate T cells against the cancer. Although still in experimental stages, clinical trials of these vaccines are uncovering their potential as a therapeutic strategy, offering hope for improved treatment outcomes in neuroblastoma. The integration of these diverse immunotherapeutic strategies reflects the dynamic evolution of cancer treatment, offering new hope for patients with neuroblastoma. Through the targeted engagement of the immune system, the development of novel therapies, and the refinement of existing treatments, the battle against neuroblastoma is being fought on multiple fronts. As research progresses, these approaches promise to further unravel the complexities of neuroblastoma and pave the way for more effective and personalized treatments, marking significant strides in the ongoing quest to conquer this challenging pediatric cancer. The rationale behind combination immunotherapy strategies in neuroblastoma lies in the recognition of the multifaceted immune evasion mechanisms employed by the tumor. By simultaneously targeting multiple checkpoints and signaling pathways, these approaches aim to potentiate anti-tumor immune responses and overcome resistance mechanisms. For instance, the combination of PD-1/PD-L1 blockade with CTLA-4 inhibition exploits complementary mechanisms of action, enhancing T cell activation and effector function. Furthermore, synergistic interactions between immune checkpoint inhibitors and targeted therapies, such as ALK inhibitors, offer the potential for improved therapeutic outcomes by concurrently addressing oncogenic drivers and immunosuppressive pathways. Preclinical models provide valuable insights into the feasibility and efficacy of these combination regimens, paving the way for clinical translation and the development of personalized treatment strategies for high-risk neuroblastoma patients. Harnessing Innate Immunity: Innate immune effectors, particularly natural killer (NK) cells, play a crucial role in tumor surveillance and elimination. The recognition of tumor cells by activating receptors on NK cells triggers cytotoxicity through the release of perfin and granzyme B, leading to target cell lysis. Strategies aimed at augmenting NK cell function in neuroblastoma immunotherapy include cytokine-based activation, such as interleukin-2 (IL-2) or interleukin-15 (IL-15) stimulation, which enhances NK cell proliferation and cytotoxicity. Additionally, adoptive transfer of ex vivo expanded NK cells offers a promising approach to bolster anti-tumor immune responses. Furthermore, bispecific antibodies designed to engage both GD2 on neuroblastoma cells and CD16A on NK cells have shown potent NK cell-mediated cytotoxicity in preclinical studies, highlighting the therapeutic potential of harnessing innate immunity in neuroblastoma immunotherapy. Targeting the Tumor Microenvironment: The immunosuppressive tumor microenvironment of neuroblastoma poses significant challenges to effective immunotherapy. Myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are key orchestrators of immune evasion within the TME, inhibiting effector T cell function and promoting tumor progression. Strategies to selectively deplete or inhibit MDSCs and Tregs hold promise for restoring anti-tumor immunity. Preclinical studies utilizing inhibitors of MDSC recruitment or function, such as CXCR2 antagonists or phosphodiesterase-5 (PDE5) inhibitors, have demonstrated enhanced T cell-mediated anti-tumor responses and improved survival outcomes in neuroblastoma models. Similarly, targeting Tregs through depletion strategies or blockade of immunosuppressive pathways represents a rational approach to unleash anti-tumor immunity within the TME. Engineering Enhanced CAR T Cells: Continued advancements in CAR T cell engineering aim to optimize therapeutic outcomes and mitigate challenges associated with neuroblastoma immunotherapy. Second-generation CAR constructs incorporating co-stimulatory domains, such as CD28 or 4-1BB, enhance CAR T cell activation and persistence within the hostile TME. Additionally, innovative approaches, including the use of inducible CAR systems or synthetic notch receptors, offer precise control over CAR T cell activity and may reduce off-tumor toxicities. Moreover, strategies to enhance CAR T cell trafficking and infiltration into neuroblastoma tumor sites, such as the expression of chemokine receptors or the use of regional delivery methods, hold promise for maximizing therapeutic efficacy while minimizing systemic toxicities. These advancements underscore the potential of engineered CAR T cell platforms in revolutionizing the landscape of neuroblastoma immunotherapy.



Biomarkers & Personalized Medicine

Biomarkers play a crucial role in guiding immunotherapy interventions, offering insights into patient response and aiding in the development of personalized treatment strategies. Neuroblastoma, one of the most common solid tumors of childhood, arises from aberrant development of neural crest cells during embryogenesis. It manifests as tumors primarily in the adrenal glands, abdomen, chest, or pelvis, exhibiting considerable heterogeneity in genetic alterations. These genetic aberrations often involve crucial oncogenes and tumor suppressor genes, such as MYCN, ALK, and PHOX2B, contributing to the diverse clinical presentations and treatment responses observed in neuroblastoma patients. The heterogeneity in neuroblastoma poses significant challenges in achieving favorable treatment outcomes, emphasizing the need for personalized medicine approaches. Immunotherapy harnesses the body's immune system to target and eliminate cancer cells, which has emerged as a promising avenue in neuroblastoma treatment. Key immunotherapeutic modalities include immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and monoclonal antibodies, each offering unique mechanisms to combat cancer progression. However, the effectiveness of immunotherapy varies among patients due to differences in tumor biology, the immune microenvironment, and host factors. Biomarkers serve as invaluable tools in deciphering these complexities and guiding treatment decisions. In the context of neuroblastoma immunotherapy, biomarkers help identify patients who are likely to respond to treatment and those at risk of adverse events. Specific biomarkers in neuroblastoma may encompass a spectrum of molecular and cellular signatures. Genetic mutations, such as amplification of the MYCN oncogene or activating mutations in the ALK gene have been identified as prognostic indicators and potential therapeutic targets. [3]Furthermore, the tumor microenvironment, characterized by the infiltration of various immune cell subsets, plays a critical role in shaping treatment response. Tumor-infiltrating lymphocytes (TILs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs) are among the immune cell populations whose abundance and activation status can influence immunotherapy outcomes. Additionally, the expression levels of immune checkpoint molecules such as programmed death-ligand 1 (PD-L1) on tumor cells or infiltrating immune cells hold prognostic significance in neuroblastoma. High PD-L1 expression has been associated with better responses to immune checkpoint inhibitors in certain cancers indicating its potential utility as a predictive biomarker in neuroblastoma immunotherapy. Additionally, in neuroblastoma, biomarkers such as GD2, CD171, and B7-H3 play crucial roles in both diagnosis and targeted therapy, serving as effective targets for CAR T-cell immunotherapy. GD2, a disialoganglioside prevalent on neuroblastoma cells but limited on normal tissues, is a prime target for CAR T-cells, enabling precise tumor cell destruction with minimal off-target effects.[4]

CD171, another neuroblastoma-associated molecule, and B7-H3, which is overexpressed in several solid tumors including neuroblastoma, offer additional targets that are less prevalent on healthy cells, potentially reducing collateral damage during treatment. While biomarkers guide clinical decisions by indicating disease presence, severity, or likely response to treatment, immunotherapy targets specifically are molecules exploited by treatments like CAR T cells to directly engage and eradicate cancer cells, illustrating a strategic focus in therapy development. [5]Personalized medicine endeavors to tailor treatment strategies based on individual patient characteristics, encompassing genetic makeup, tumor biology, and immune profile. In neuroblastoma, personalized medicine approaches leverage biomarker data to select optimal treatment regimens, minimize toxicity, and enhance therapeutic efficacy. For example, patients with neuroblastoma harboring ALK mutations may derive substantial benefit from targeted therapies such as ALK inhibitors which specifically target the oncogenic driver. Moreover, immunotherapy strategies can be finely tuned based on comprehensive biomarker profiles to optimize treatment responses and mitigate the risk of immune-related adverse events. By integrating biomarker-guided approaches into clinical practice, clinicians can navigate the intricate landscape of neuroblastoma treatment with greater precision and effectiveness, ultimately improving patient outcomes and quality of life.



Case Studies in Immunotherapy for Neuroblastoma

Neuroblastoma, a predominant pediatric malignancy, presents significant challenges in management, particularly in patients with high-risk neuroblastoma (HR-NB) due to frequent relapses and chemoresistance. The first case is of a 3-year-old female diagnosed with HR-NB, detailing the progression, treatment responses, and the monitoring of minimal residual disease (MRD) through neuroblastoma-associated mRNAs (NB-mRNAs) in peripheral blood (PB) and bone marrow (BM). Highlighting the unique instance of higher MRD levels in PB than in BM preceding relapse/regrowth, this study underscores the potential of PB-MRD as a sensitive prognostic marker and its implications in tailoring immunotherapy regimens.

High-risk neuroblastoma (HR-NB) is characterized by its aggressive nature and propensity for relapse, often attributed to minimal residual disease (MRD). The quantification of neuroblastoma-associated mRNAs (NB-mRNAs) in PB and BM provides insights into the disease's persistence post-treatment, often undetectable through conventional imaging. This paper examines a detailed case study where PB-MRD, typically challenging to discern due to its lower levels compared to BM-MRD, demonstrated higher values prior to relapse, suggesting its potential role in early detection and intervention. The subject, a 3-year-old female diagnosed with HR-NB, presented with an abdominal mass and was treated as per the national standard protocol, including systemic induction and consolidation therapies followed by local therapy. Despite achieving complete remission, the patient experienced two subsequent relapses, the first six months post-maintenance therapy and the second 14 months after the first. Notably, PB-MRD levels were initially lower than BM-MRD but increased and exceeded BM levels prior to each relapse/regrowth. This retrospective analysis focuses on serial MRD assessments through quantitative NB-mRNAs analyses in both PB and BM samples. MRD dynamics were correlated with clinical outcomes, response to salvage chemotherapy, and anti-GD2 immunotherapy across various stages of treatment. [6]Initial MRD monitoring showed PB-MRD levels 100 times lower than BM-MRD at diagnosis, reflecting the established challenges in detecting PB-MRD. However, subsequent assessments revealed a significant increase in PB-MRD, surpassing BM-MRD levels before each relapse/regrowth, aligning with clinical indicators of disease progression. The findings challenge the traditional perspective that PB-MRD is less indicative of MRD status due to typically lower detectability. This case illustrates that PB-MRD, when rising above BM-MRD, can serve as an early prognostic indicator, potentially guiding more timely interventions and adjustments in treatment protocols, including the optimization of immunotherapy strategies. MRD monitoring in HR-NB can benefit from a dual approach involving both PB and BM samples. The observed patterns in PB-MRD suggest it may serve as an important biomarker for early relapse detection, thus aiding in the strategic planning of immunotherapy regimens. This case contributes to the broader understanding of MRD dynamics and its practical implications in managing HR-NB. Secondly, the objective of this is to examine detailed case studies of high-risk neuroblastoma patients who underwent immunotherapy treatment with dinutuximab beta, exploring their clinical responses, treatment protocols, and management of adverse effects. This study is based on the experiences of a single center in Bratislava, which provides insights into real-world clinical applications and outcomes of dinutuximab beta in routine practice. This study focuses on a retrospective review of medical records from the Children's Hematology and Oncology Clinic in Bratislava, covering patients diagnosed between 2017 and 2020. This retrospective study reviewed the medical records of 31 patients diagnosed with neuroblastoma, identifying 7 high-risk cases treated with dinutuximab beta. Treatment involved continuous intravenous infusion of dinutuximab beta at a dose of 10 mg/m2/day over 10 days for 5 cycles. This treatment followed an induction phase and consolidation therapy, including chemotherapy, surgery, and autologous stem cell transplantation (ASCT). The study evaluated treatment tolerability and clinical outcomes, with supportive therapies administered to manage adverse events (AEs). The first patient characteristics included a median age at diagnosis at 22.5 months, 3 males, 4 females and all patients had poorly differentiated neuroblastoma with segmental chromosomal aberrations; half had MYCN amplification. Six patients achieved complete remission (CR) post-treatment, with one showing stable disease (SD). Median duration of response was 21.5 months and 5 patients received the full 5 cycles of dinutuximab beta, while one discontinued due to severe neurotoxicity but still achieved CR after subsequent management. Most AEs were mild to moderate and included pain, capillary leak syndrome, nausea, vomiting, anorexia, and mild allergic reactions. AEs were predominantly managed with supportive care, including hydration, analgesia, and antiallergic measures. Severe neurotoxicity occurred in one case, leading to the discontinuation of dinutuximab beta; symptoms were reversible with intensive care. The use of dinutuximab beta in these patients has highlighted the effectiveness of this immunotherapy in achieving substantial disease remission and managing high-risk neuroblastoma. The majority of patients not only responded positively to the treatment but also tolerated it well, with manageable AEs. This aligns with previous clinical trial data that highlighted improved survival outcomes with dinutuximab beta. However, the study also highlights the critical nature of supportive care in managing AEs and ensuring the success of immunotherapy in pediatric patients. The case of severe neurotoxicity demonstrates the importance of preparedness and responsiveness in clinical settings to address potential severe reactions. The study's limitations include its retrospective nature, the small sample size, and the lack of a comparison group. These factors may constrain the generalizability of the findings. This case series confirms the beneficial role of dinutuximab beta as part of maintenance therapy in treating high-risk neuroblastoma, emphasizing the need for experienced clinical settings to manage treatment complexities effectively. Future studies should aim to expand on these findings with larger cohorts and comparative data to further validate the routine clinical use of dinutuximab beta in pediatric oncology.[7]

Future Directions in Immunotherapy for Neuroblastoma

Neuroblastoma, a prevalent pediatric solid tumor, poses significant challenges due to its diverse clinical behavior, often influenced by its biological characteristics. The tumor is notorious for its early onset, spontaneous regression in infants, and frequent metastatic presence at diagnosis in children over one year old. Despite advancements in treatment, the survival rate for high-risk patients remains under 50%, highlighting the need for more effective therapeutic strategies. The future directions of immunotherapy research and treatment for neuroblastoma are both promising and expansive, focusing on overcoming the unique challenges posed by the highly immunosuppressive tumor microenvironment (TME) of this pediatric cancer. A significant trend is the exploration of combination strategies to enhance the effectiveness of existing treatments and overcome resistance. Examples include the concurrent targeting of GD2 with other immune elements such as tumor-associated macrophages, natural killer cells, and immune checkpoint proteins like B7-H3. [8]Combining these therapies aims to achieve synergistic effects, potentially enhancing the immune system's ability to fight the cancer more effectively. Advanced targeting strategies like efforts being made to refine targeting strategies for existing therapies. For instance, the dual targeting of GD2 and CD47 has shown promise in preclinical models by facilitating both enhanced antibody-dependent cellular cytotoxicity and increased phagocytosis of cancer cells. Such strategies are currently being evaluated in clinical trials and could become critical components of future neuroblastoma treatment protocols. Engineering cell therapies such as the development of chimeric antigen receptor (CAR) T-cell therapies specifically designed for neuroblastoma is progressing. For example, CAR-T cells targeting GD2 as well as other neuroblastoma-specific antigens like B7-H3 are being developed. These therapies aim to improve targeting efficacy and reduce the likelihood of tumor escape due to antigen heterogeneity. There's also a move towards using innate immune cells, such as natural killer T (NKT) cells and macrophages, which might offer advantages in terms of availability and reduced risk of graft-versus-host disease. Research continues into ways to make neuroblastoma cells more immunogenic (easily recognized and attacked by the immune system). This includes modulation of pathways like the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, which can enhance the immune response against tumors by promoting inflammation within the TME. Although traditional immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockers) have been less effective in neuroblastoma due to its low mutational burden and "cold " immune status, novel approaches to stimulate these pathways are being tested. This includes the development of vaccines or adjuvants that could modify the TME or directly enhance the expression of molecules like PD-L1 on tumor cells, making them more susceptible to checkpoint blockade. A continuous goal is to improve the safety profiles of immunotherapies and reduce their associated toxicities, which are often significant in pediatric populations. Strategies include refining dosing schedules, developing more targeted delivery systems, and using humanized rather than murine antibodies to reduce immune reactions. The potential for combining radiotherapy with STING agonists is under consideration. Radiotherapy can increase tumor immunogenicity by causing DNA damage, and STING activation can further enhance immune responses against the tumor, potentially overcoming resistance to other forms of immunotherapy. Historically, treatment regimens for high-risk neuroblastoma have included chemotherapy, surgical resection, stem cell transplantation, and radiation therapy. The incorporation of immunotherapeutic approaches, notably the anti-GD2 antibody dinutuximab, has markedly improved outcomes by targeting specific tumor-associated antigens and modulating the immune response. However, the unique and suppressive tumor microenvironment (TME) of neuroblastoma complicates the efficacy of these therapies. Neuroblastoma's TME is characterized as immunosuppressive, often lacking antitumor immune cells while being enriched with immune-suppressive cells. This environment not only supports tumor growth but also resists conventional and immune-based therapies. The immune evasion tactics of neuroblastoma, such as downregulation of MHC molecules and secretion of immunosuppressive cytokines, reduce the effectiveness of immunotherapy. Recent advancements in neuroblastoma treatment are focusing on overcoming these challenges. Key areas include adoptive cell therapy, CAR T-cell therapies are being explored, although their development is hampered by the TME's suppressive nature. Additionally, targeted monoclonal antibodies, beyond dinutuximab, new monoclonal antibodies are under investigation to target other tumor-associated antigens. Lastly, combination therapies combining immunotherapy with traditional treatments or other novel agents show promise in enhancing therapeutic outcomes. The future of neuroblastoma treatment relies on a deeper understanding of the tumor's biological and immunological underpinnings. Innovations such as personalized medicine, where treatment is tailored based on individual tumor characteristics, and the exploration of novel immune targets are expected to drive progress in this field. Clinical trials continue to be pivotal in evaluating the potential of new therapies. Immunotherapy holds significant promise for transforming the treatment landscape of neuroblastoma, particularly for high-risk groups. [9]Despite current challenges, ongoing research and clinical trials are paving the way for more effective and less toxic treatment options. As understanding of the TME and its interaction with the immune system improves, new therapeutic strategies that can effectively harness the immune response against neuroblastoma are

anticipated to emerge, offering hope for improved survival rates and better quality of life for affected children. In the near future, advancements in immunotherapy for neuroblastoma are expected to focus on enhancing the specificity and efficacy of CAR T-cell therapies through the integration of dual-targeting strategies that aim to minimize off-target effects and reduce relapse rates. Another imminent development is the optimization of synNotch technology, which allows for more precise control of immune activation, thereby increasing the safety profile of treatments administered to young patients. Over the long term, the exploration of combination therapies that integrate immunotherapy with genetic editing tools like CRISPR, to correct oncogenic mutations directly in neuroblastoma cells, may become a viable research area. Additionally, the use of artificial intelligence to better predict individual responses to specific immunotherapies could tailor treatments more effectively, potentially revolutionizing how neuroblastoma is managed clinically. The future of immunotherapy for neuroblastoma involves a multidirectional approach that includes enhancing the immunogenicity of the tumor, refining and combining existing therapies, and innovating new cellular and molecular strategies. These efforts aim to improve overall outcomes, extend survival, and enhance the quality of life for children affected by this challenging cancer.

Conclusion:-

The role of immunotherapy in the treatment of neuroblastoma represents a significant advancement in pediatric oncology, offering a beacon of hope for improving the outcomes of patients with this challenging disease. Through the detailed examination of case studies, such as the use of dinutuximab beta, it is evident that immunotherapeutic strategies have the potential to significantly enhance survival rates and quality of life for high-risk neuroblastoma patients. Monoclonal antibodies targeting the GD2 antigen, along with emerging approaches like checkpoint inhibitors and adoptive cell therapies, illustrate the dynamic and evolving landscape of cancer treatment. These methods leverage the body's own immune mechanisms to fight cancer, highlighting a shift towards more personalized and precise medical interventions.

However, the integration of immunotherapy into neuroblastoma treatment protocols also highlights the complexity of managing pediatric cancers. The variable efficacy among patients, the potential for severe adverse effects, and the challenges in predicting treatment responses necessitate ongoing research and clinical trials. Furthermore, the development of precise biomarkers for tailoring treatments and monitoring responses is critical for optimizing immunotherapy strategies. As this advances, it is crucial to balance efficacy with safety, ensuring that these potent therapies are delivered in a manner that maximizes benefit while minimizing harm to young patients.

Looking forward, the future of neuroblastoma treatment will likely involve a combination of traditional therapies and innovative immunotherapeutic strategies. Continued research into the tumor microenvironment, genetic markers, and immune modulation will be key in developing more effective and less toxic treatments. The promise of immunotherapy in transforming the landscape of neuroblastoma treatment is undeniable, but it requires a concerted effort from researchers, clinicians, and the broader scientific community to turn these scientific insights into life-saving treatments. As these approaches are refined and their implications are better understood, the hope is to not only extend survival but also enhance the quality of life for children battling neuroblastoma, ultimately moving towards more curative outcomes in pediatric oncology.

References:-

1. Valent, A. et al. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. Journal of Pathology**198**, (2002).
2. Achbergerová, M., Hederová, S., Hrašková, A. &Kolenová, A. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava. Medicine (United States)**101**, (2022).
3. McNerney, K. et al. Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in TH-MYCN mice. bioRxiv (2021).
4. Cheung, I. Y. et al.Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression. Journal of Clinical Oncology**39**, (2021).
5. Heitzeneder, S. et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell**40**, (2022).
6. Yu, A. L. et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. New England Journal of Medicine**363**, (2010).

7. Inoue, S. et al. Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high-risk neuroblastoma: A case report. Oncol Lett**26**, (2023).
8. Moghimi, B. et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun**12**, (2021).
9. Kennedy, P. T., Zannoupa, D., Son, M. H., Dahal, L. N. & Woolley, J. F. Neuroblastoma: An ongoing cold front for cancer immunotherapy. Journal for ImmunoTherapy of Cancer vol. 11 Preprint at https://doi.org/10.1136/jitc-2023-007798 (2023).